Prognostic significance of pretreatment serum lactate dehydrogenase-to-albumin ratio in gastric cancer
View/ Open
Access
info:eu-repo/semantics/openAccessDate
2020Author
Aday, UlaşTatlı, Faruk
Akpulat, Faik V.
İnan, Mazlum
Kafadar, Mehmet Tolga
Bilge, Hüseyin
Başol, Ömer
Oǧuz, Abdullah
Metadata
Show full item recordCitation
Aday, U., Tatlı, F., Akpulat, F. V., İnan, M., Kafadar, M. T., Bilge, H. ve diğerleri. (2020). Prognostic significance of pretreatment serum lactate dehydrogenase-to-albumin ratio in gastric cancer. Wspolczesna Onkologia, 24(3), 145-149.Abstract
Aim of the study: To investigate the prognostic role of lactate dehydrogenase-to-albumin ratio (LAR) in gastric cancer patients undergoing curative resection. Material and methods: A retrospective study was conducted including resectable gastric cancer patients. According to the time-dependent receiver operating characteristics (ROC) analysis, the optimal threshold for pretreatment LAR was 5.5. The Kaplan-Meier method, Cox regression univariate and multivariate analyses were used to analyze the prognostic factors for disease-free survival and overall survival (OS). Results: The study cohort consisted of 81 patients, mean age was 60.2 ±13.8 (range, 29-87) years and 55 (67.9%) were male. The median OS time was 34.8 and 45 months in patients with LAR ≥ 5.5 (n = 50) and LAR < 5.5 (n = 31), respectively. Kaplan-Meier curves showed that with the increase in LAR there was reduced survival, but it was not statistically significant (p = 0.278). Multivariate analyses revealed that the positive lymph node ratio above 20% was an independent predictor in resectable gastric cancer patients (OR = 6.281, 95% CI: 1.135-34.767, p = 0.035). Conclusions: With the increase in LAR survival in gastric cancer decreased, but it was not statistically significant. Studies involving a large patient series are needed.
WoS Q Category
N/AScopus Q Category
Q3Volume
24Issue
3URI
https://www.termedia.pl/Prognostic-significance-of-pretreatment-serum-lactate-dehydrogenase-to-albumin-ratio-in-gastric-cancer,3,42181,0,1.htmlhttps://hdl.handle.net/11468/7256